The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.

The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.

Adenovirus vaccine vectors generated from new viral serotypes are routinely screened in pre-clinical laboratory animal models to identify the most immunogenic and efficacious candidates for further evaluation in clinical human and veterinary settings. Here, we show that studies in a laboratory speci...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Dicks, M, Guzman, E, Spencer, A, Gilbert, S, Charleston, B, Hill, A, Cottingham, M
Natura:	Journal article
Lingua:	English
Pubblicazione:	Elsevier 2015

Documenti analoghi

Uncovering the mechanisms of adenovirus vector immunogenicity
di: Dicks, M, et al.
Pubblicazione: (2013)

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
di: Dicks, M, et al.
Pubblicazione: (2012)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
di: Dicks, M, et al.
Pubblicazione: (2015)

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
di: Matthew D J Dicks, et al.
Pubblicazione: (2012-01-01)

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
di: Warimwe, G, et al.
Pubblicazione: (2013)

Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species
di: Dicks, M, et al.
Pubblicazione: (2011)

Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.
di: Cottingham, MG, et al.
Pubblicazione: (2012)

Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors
di: Cottingham, MG, et al.
Pubblicazione: (2011)

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
di: Dudareva, M, et al.
Pubblicazione: (2009)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
di: Ewer (nee Russell), K, et al.
Pubblicazione: (2017)

Novel adenovirus vaccine vectors
di: Dicks, M
Pubblicazione: (2013)

Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley Fever
di: Warimwe, G, et al.
Pubblicazione: (2016)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
di: Katie Ewer, et al.
Pubblicazione: (2017-12-01)

Simian adenoviruses as vaccine vectors
di: Morris, S, et al.
Pubblicazione: (2016)

Simian adenoviruses as vaccine vectors
di: Morris, S, et al.
Pubblicazione: (2016)

Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys
di: Catherine Collignon, et al.
Pubblicazione: (2020-11-01)

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
di: Green, C, et al.
Pubblicazione: (2015)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
di: Adam Berg, et al.
Pubblicazione: (2021-10-01)

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
di: Biswas, S, et al.
Pubblicazione: (2011)

A monovalent chimpanzee adenovirus Ebola vaccine — preliminary report
di: Rampling, T, et al.
Pubblicazione: (2015)

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs
di: Joe, CCD, et al.
Pubblicazione: (2021)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
di: Ewer (nee Russell), K, et al.
Pubblicazione: (2016)

T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load.
di: Roshorm, Y, et al.
Pubblicazione: (2012)

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
di: Green, C, et al.
Pubblicazione: (2023)

Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa
di: Zhiquan Xiang, et al.
Pubblicazione: (2006-10-01)

Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors
di: Steven Tuyishime, et al.
Pubblicazione: (2018-05-01)

Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity.
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2012)

Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2012)

Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection
di: Po-Wei Liao, et al.
Pubblicazione: (2021-12-01)

Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
di: Nébié, I, et al.
Pubblicazione: (2014)

A lyophilised formulation of chimpanzee adenovirus vector for long-term stability outside the deep-freeze cold chain
di: Frédéric Mathot, et al.
Pubblicazione: (2025-01-01)

Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection
di: Mingqing Lu, et al.
Pubblicazione: (2023-11-01)

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
di: Ewer, K, et al.
Pubblicazione: (2013)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
di: Antrobus, R, et al.
Pubblicazione: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
di: Antrobus, R, et al.
Pubblicazione: (2014)

Lichenoid drug reaction post-COVID vaccination with the modified chimpanzee adenovirus
di: Paola Garcia-Mendoza, et al.
Pubblicazione: (2022-01-01)

Cytokine Responses to Adenovirus and Adenovirus Vectors
di: Svetlana Atasheva, et al.
Pubblicazione: (2022-04-01)

Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients
di: Hua Zhao, et al.
Pubblicazione: (2018-03-01)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
di: Stylianou, E, et al.
Pubblicazione: (2015)

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses
di: Sonia Marquez-Martinez, et al.
Pubblicazione: (2024-01-01)